Vigil Neuroscience, Inc./$VIGL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vigil Neuroscience, Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.
Ticker
$VIGL
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
67
Website
VIGL Metrics
BasicAdvanced
$384M
-
-$2.05
3.45
-
Price and volume
Market cap
$384M
Beta
3.45
52-week high
$8.10
52-week low
$1.31
Average daily volume
813K
Financial strength
Current ratio
2.965
Quick ratio
2.879
Long term debt to equity
17.848
Total debt to equity
19.491
Profitability
EBITDA (TTM)
-91.273
Management effectiveness
Return on assets (TTM)
-49.38%
Return on equity (TTM)
-102.70%
Valuation
Price to book
5.77
Price to tangible book (TTM)
5.77
Price to free cash flow (TTM)
-6.35
Free cash flow yield (TTM)
-15.75%
Free cash flow per share (TTM)
-1.268
Growth
Earnings per share change (TTM)
-3.12%
3-year earnings per share growth (CAGR)
-31.70%
Bulls say / Bears say
Sanofi's acquisition of Vigil Neuroscience for $470 million, including an upfront payment of $8 per share and a contingent value right of $2 per share, underscores confidence in Vigil's pipeline and potential for growth. (reuters.com)
Vigil's VG-3927, an oral drug in development for Alzheimer's disease, has attracted significant investment, including a $40 million equity investment from Sanofi in June 2024, highlighting its promising prospects. (reuters.com)
The FDA's removal of the partial clinical hold on VG-3927's Phase 1 trial in September 2024 allows for the continuation of its development, potentially accelerating its path to market. (dnews.com)
The acquisition by Sanofi at $8 per share, with an additional $2 contingent on VG-3927's commercial success, may limit immediate upside potential for current shareholders. (reuters.com)
Wedbush downgraded Vigil Neuroscience from a 'strong-buy' to a 'hold' rating in May 2025, reflecting concerns about the company's valuation and future prospects. (techdows.com)
A class action investigation into the merger with Sanofi could introduce legal uncertainties and potential delays in the acquisition process. (tradingview.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
VIGL News
AllArticlesVideos
VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL
Business Wire·3 weeks ago
VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL
Business Wire·2 months ago
Shareholder Alert: The Ademi Firm Investigates Whether Vigil Neuroscience Inc. Is Obtaining a Fair Price for Its Public Shareholders
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vigil Neuroscience, Inc. stock?
Vigil Neuroscience, Inc. (VIGL) has a market cap of $384M as of August 01, 2025.
What is the P/E ratio for Vigil Neuroscience, Inc. stock?
The price to earnings (P/E) ratio for Vigil Neuroscience, Inc. (VIGL) stock is 0 as of August 01, 2025.
Does Vigil Neuroscience, Inc. stock pay dividends?
No, Vigil Neuroscience, Inc. (VIGL) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Vigil Neuroscience, Inc. dividend payment date?
Vigil Neuroscience, Inc. (VIGL) stock does not pay dividends to its shareholders.
What is the beta indicator for Vigil Neuroscience, Inc.?
Vigil Neuroscience, Inc. (VIGL) has a beta rating of 3.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.